Pharmaceuticals, Biotechnology and Life Sciences
Basilea Pharmaceutica and Pfizer have extended their license agreement for Basilea’s antifungal Cresemba to China and sixteen countries in Asia…
Basilea Pharmaceutica International has amended its existing license agreement for Europe, Russia, Turkey and Israel with Pfizer Inc. for Basilea’s…
Basilea Pharmaceutica said Thursday its licensing partner Pfizer recently launched the antifungal drug Cresemba (isavuconazole) in Spain. Pfizer is now commercializing…
South Africa’s competition watchdog has launched an investigation into three drug companies accused of over-charging for cancer medicines, the agency’s chief said on Tuesday.
Astellas Pharma and Pfizer have amended the protocol for the registrational PROSPER trial to test the efficacy and safety of Xtandi in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC).
United States Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Pfizer’s Xeljanz (tofacitinib citrate) 5 mg twice daily (BID) and XeljanzXR extended release 11 mg once daily use the treatment of adult patients with active psoriatic arthritis (PsA).
Karo Pharma has reached a second milestone from its collaboration with Pfizer on the RORgamma project amounting to $2 million.
Pfizer has decided to cancel listing of its stocks from the UK listing Authority List. The company said on Wednesday it also cancels trading on the main London Stock Exchange market.
Pfizer has reported 11% growth for full-year 2016 revenues, reaching $52.8 billion, including the business from Hospira and the legacy of Medivation. Net income for full year was $7,215 million which is up 4% from last years total net income of $6,960.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended Pfizer’s Xeljanz (tofacitinib citrate)…